← Screener · Thematic / sector
CUREGlobal X · Equity - Global Sectors · Equity · Global ex-Australia
Global X S&P Biotech ETF
Fee p.a.
0.45%
ASX report
Fund size
A$47m
12m flow A$-1.9m
Yield
0.0%
0 payments / yr
Volatility 3y
27.4%
annualised
Max DD 3y
−28.4%
all-time −59.8%
Listed
2018
12 Nov 2018 · spread 0.35%
$8k$10k$12k$14k$16k$18k$20k$22k201820192020202120222023202420252026
Performance
Period
Total
ASX
1 month
9.4%
−6.4%
3 months
26.2%
—
6 months
29.7%
—
Year to date
25.7%
—
1 year
59.8%
62.7%
3 years p.a.
22.2%
19.9%
5 years p.a.
4.2%
5.0%
10 years p.a.
—
—
Since listing p.a.
8.9%
—
Total return to 4 Sept 2026, distributions reinvested, before franking. ASX figures are to 31 July 2026 and gross of franking, so they run higher for franked Australian funds.
Sharpe 3y 0.67Vol 1y 27.3%Vol 5y 31.1%Max DD 1y −11.7%Max DD 5y −50.5%Best year 38.3%71% positive years
Calendar-year returns
2019
35.6%
2020
38.3%
2021
−17.1%
2022
−23.0%
2023
10.6%
2024
8.1%
2025
25.3%
2026
25.7%
Where the money is
Look-through exposure as at 2 Sept 2026 · 146 securities · top 10 = 15.6%
Country
United States100.0%
Top holdings
MODERNA INCUnited States
3.0%
TWIST BIOSCIENCEUnited States
1.8%
HALOZYME THERAPEUnited States
1.4%
KYMERA THERAPEUTUnited States
1.4%
NATERA INCUnited States
1.4%
PRAXIS PRECISIONUnited States
1.4%
REVOLUTION MEDICUnited States
1.3%
TRAVERE THERAPEUUnited States
1.3%
ORUKA THERAPEUTIUnited States
1.3%
REGENERON PHARMUnited States
1.3%
DIANTHUS THERAPEUnited States
1.3%
PROTAGONIST THERUnited States
1.3%
INSMED INCUnited States
1.3%
CG ONCOLOGY INCUnited States
1.2%
VAXCYTE INCUnited States
1.2%
Top 15 of 146 holdings.
Most similar funds
Overlap is the share of the portfolio held in common, look-through. Correlation is of daily returns. High overlap means close substitutes.
Code
Fund
Fee
Overlap
Corr 3y